Taro Pharma, the US division of India's top drug maker Sun Pharmaceuticals Ltd., has reached a agreement with Antibe Therapeutics, a biotech firm from Canada. After the announcement, Sun Pharmaceuticals has agreed to acquire 100% share in Antibe...
Gland Pharma announced that it has secured the establishment inspection report (EIR) from the US drug regulatory authority for its Dundigal site in Hyderabad, marking the conclusion of the inspection. The US Food and Drug Administration (USFDA)...
Annovis Bio Inc., a company in the late stages of clinical drug development focused on innovative therapies for neurodegenerative disorders like Alzheimer’s disease (AD) and Parkinson’s disease (PD), revealed that it received the US patent for...
PulseSight Therapeutics SAS, a biotech firm focused on ophthalmology that creates groundbreaking non-viral vector therapies utilizing minimally-invasive delivery methods, has announced it has filed a Clinical Trial Authorization (CTA) with the...
MedMira Inc. (MedMira) announced that it has secured approval from Health Canada for its Reveal Rapid G4 HIV-1/2 Test (Reveal HIV test) intended for Point-of-Care (POC) applications. The Reveal HIV rapid test boasts a sensitivity of 99.64% and a...
Japanese pharmaceutical firm Takeda opened its inaugural Innovation Capability Centre (ICC) in Bengaluru, signifying its first venture in Asia. The ICC plans to hire 750 professionals, such as software engineers, data scientists, and cybersecurity...
Lyndra Therapeutics, a biopharmaceutical company in the clinical stage, has formed a strategic partnership with Thermo Fisher Scientific Inc., wherein Thermo Fisher will offer global clinical research and commercial manufacturing services to...
Alembic Pharmaceuticals Ltd announced that it has secured final approval from the US health regulator for its generic variant of Brexpiprazole tablets, which are used in treating major depressive disorder. The company announced that the US Food &...
The Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) from AstraZeneca and Daiichi Sankyo has been accepted and awarded Priority Review status in the US for treating adult patients with locally advanced or metastatic...
Rappta Therapeutics (Rappta), focused to creating first-in-class anti-cancer therapies that activate protein phosphatase 2A (PP2A), has announced a global exclusive licensing agreement with SpringWorks Therapeutics (SpringWorks) for RPT04402...
, CDSCO.jpg)
